PEG RELIGRAST-6 MG

About

This medication is a pegylated form of granulocyte colony-stimulating factor (G-CSF), designed to provide sustained neutrophil support with a single dose per chemotherapy cycle. The pegylation process, involving the covalent attachment of a polyethylene glycol (PEG) molecule, significantly extends its half-life by reducing renal clearance, thereby allowing for less frequent administration compared to non-pegylated G-CSF. It functions by stimulating the production, maturation, and activation of neutrophils from the bone marrow, which are critical components of the immune system. Its primary indication is to reduce the incidence of febrile neutropenia and decrease the duration of neutropenia in patients receiving myelosuppressive anti-cancer chemotherapy, thereby mitigating the risk of serious infections and supporting the continuity of cancer treatment regimens.

Uses

• Reduce incidence of febrile neutropenia in chemotherapy.
• Decrease duration of neutropenia.
• Support neutrophil recovery after cytotoxic chemotherapy.
• Prevent infection in cancer patients.

Directions For Use

Administer subcutaneously once per chemotherapy cycle, typically 24 hours after chemotherapy. Do not administer within 14 days before or 24 hours after chemotherapy.

Benefits

• Single dose per chemotherapy cycle.
• Sustained neutrophil support.
• Reduces risk of serious infections.
• Accelerates neutrophil recovery.
• Allows for timely chemotherapy cycles.
• Improved patient convenience.

Side Effects

• Bone pain
• Muscle aches
• Headache
• Fatigue
• Nausea
• Injection site reactions
• Splenomegaly (rare)
• Allergic reactions (rare)
• Acute respiratory distress syndrome (rare)
• Glomerulonephritis (rare)
• Leukocytosis
• Thrombocytopenia (rare)

Safety Measures

• Alcohol - No specific interaction known; however, maintaining overall health is important during treatment.
• Pregnancy - Use only if clearly needed; potential risks to the fetus should be weighed against maternal benefits.
• Breastfeeding - Excretion into breast milk is unknown; caution is advised, and a physician should be consulted.
• Liver - Generally safe; no specific dose adjustment required for mild to moderate hepatic impairment.
• Kidney - Generally safe; no specific dose adjustment required for mild to moderate renal impairment.
• Lung - Use with caution in patients with pre-existing lung conditions; monitor for respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.